Early signal, structured validation.
NeuralPoint is a clinical-stage platform advancing structured evaluation focused on OSA (AHI 5–15) - where diagnostic ambiguity is highest and clinical need is greatest.
Results and data.
Early validation demonstrates meaningful correlation with polysomnography-derived outcomes - and intra-category differentiation within the most diagnostically challenging segment.
Key performance indicators
Total participants enrolled during ongoing clinical validation studies.
Investigational classification performance in identifying physiologic patterns associated with OSA.
Intra-category differentiation within the most clinically ambiguous OSA segment (AHI 5–15), based on early investigational data.
Published clinical evidence.
Peer-reviewed publications establishing the scientific foundation of the NeuralPoint platform.
Clinical Validation of tmEMG
Pilot study of a novel transmembranous EMG device - published in Muscle & Nerve, selected as the cover article.
Deep Learning Enhanced tmEMG in OSA Diagnosis
An investigational study demonstrated approximately 82% classification performance in identifying physiologic patterns associated with OSA (BMC Neuroscience); results are preliminary and require further validation.
OSA Neuromuscular Function White Paper
Co-authored by a KOL panel - demonstrates how NeuralPoint's technology could change the OSA diagnostic paradigm.
Validation roadmap.
Advancing multi-center academic validation to expand generalizability and establish clinical utility across patient populations.
Academic Collaboration & Engagement
NeuralPoint is advancing multi-center validation discussions with 3 academic sleep medicine centers.
Focus areas
- Structured workflow integration
- Inter-operator reliability
- Longitudinal signal stability
Dataset & Workflow Expansion
The roadmap focuses on structured workflow integration and expanding dataset diversity.
Establishing Clinical Utility
Establishing the clinical utility of the biomarker index for routine sleep medicine practice.